中國國航(00753.HK)向特定對象發行A股申請獲上海證券交易所審核通過
格隆匯10月21日丨中國國航(00753.HK)公吿,中國國際航空股份有限公司(以下簡稱“公司”)於近日收到上海證券交易所上市審核中心向公司出具的《關於中國國際航空股份有限公司向特定對象發行股票審核意見的通知》,認為公司向特定對象發行股票申請符合發行條件、上市條件和信息披露要求。
公司本次向特定對象發行A股股票事項尚需經中國證券監督管理委員會作出同意註冊決定後方可實施,最終能否獲得中國證券監督管理委員會同意註冊的決定及其時間尚存在不確定性。公司將根據進展情況,嚴格按照上市公司向特定對象發行股票相關法律法規的規定和要求及時履行信息披露義務,敬請投資者注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.